Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?

Literature DB >> 19112734

New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?

Alberto Grossi¹, Giancarlo Maria Liumbruno.

Abstract

Entities: Disease

Mesh：

Substances：
Antineoplastic Agents

Year: 2008 PMID： 19112734 PMCID： PMC2626911 DOI： 10.2450/2008.0009-08

Source DB: PubMed Journal: Blood Transfus ISSN： 1723-2007 Impact factor: 3.443

× No keyword cloud information.

54 in total

1. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.

Authors: Pellegrino Musto; Antonietta Falcone; Grazia Sanpaolo; Carlo Bodenizza
Journal: Leuk Res Date: 2005-10-10 Impact factor: 3.156

2. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

Authors: Paul G Richardson; Robert L Schlossman; Edie Weller; Teru Hideshima; Constantine Mitsiades; Faith Davies; Richard LeBlanc; Laurence P Catley; Deborah Doss; Kathleen Kelly; Mary McKenney; Julie Mechlowicz; Andrea Freeman; Reggie Deocampo; Rebecca Rich; Joan J Ryoo; Dharminder Chauhan; Kathe Balinski; Jerome Zeldis; Kenneth C Anderson
Journal: Blood Date: 2002-11-01 Impact factor: 22.113

3. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

Authors: L R Silverman; J F Holland; R S Weinberg; B P Alter; R B Davis; R R Ellison; E P Demakos; C J Cornell; R W Carey; C Schiffer
Journal: Leukemia Date: 1993-05 Impact factor: 11.528

4. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.

Authors: R S Negrin; R Stein; J Vardiman; K Doherty; J Cornwell; S Krantz; P L Greenberg
Journal: Blood Date: 1993-08-01 Impact factor: 22.113

5. Proposals for the classification of the myelodysplastic syndromes.

Authors: J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal: Br J Haematol Date: 1982-06 Impact factor: 6.998

Review 6. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.

Authors: Pellegrino Musto
Journal: Leuk Res Date: 2004-04 Impact factor: 3.156

7. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.

Authors: E Hellström-Lindberg; G Birgegård; M Carlsson; J Carneskog; I M Dahl; I Dybedal; G Grimfors; K Merk; J M Tangen; I Winqvist
Journal: Leuk Lymphoma Date: 1993-10

3. Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.

Authors: Li-Min Sun; Cheng-Li Lin; Ming-Chia Lin; Ji-An Liang; Chia-Hung Kao
Journal: Medicine (Baltimore) Date: 2015-05 Impact factor: 1.889

3 in total

New drugs in the treatment of myelodysplastic syndromes: are they changing the role of transfusion support?

1. Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes.

2. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma.

3. Effects of treatment with 5-azacytidine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes.

4. Treatment of the anemia of myelodysplastic syndromes using recombinant human granulocyte colony-stimulating factor in combination with erythropoietin.

5. Proposals for the classification of the myelodysplastic syndromes.

Review 6. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives.

7. A combination of granulocyte colony-stimulating factor and erythropoietin may synergistically improve the anaemia in patients with myelodysplastic syndromes.

8. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies.

9. Treatment of myelodysplastic syndromes with valproic acid alone or in combination with all-trans retinoic acid.

10. The use of r-HuEpo in the treatment of anaemia related to myelodysplasia (MDS).

1. Progress in the treatment of myelodysplastic syndromes.

Review 2. Lenalidomide-induced acute liver failure.

3. Radiotherapy- and chemotherapy-induced myelodysplasia syndrome: a nationwide population-based nested case-control study.